Jacobs Levy Equity Management’s Allogene Therapeutics ALLO Stock Holding History

Jacobs Levy Equity Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.03M	Sell	1,455,103 -558,405	-28%	-$1.23M	0.01%	515
2026 Q1	$4.91M	Buy	+2,013,508	New	+$4.04M	0.02%	419
2024 Q3	–	Sell	-878,955	Closed	-$2.05M	–	945
2024 Q2	$2.05M	Buy	+878,955	New	+$2.59M	0.01%	592
2023 Q1	–	Sell	-11,217	Closed	-$70.6K	–	952
2022 Q4	$70.6K	Sell	11,217 -524,151	-98%	-$4.85M	﹤0.01%	930
2022 Q3	$5.78M	Buy	+535,368	New	+$7.28M	0.05%	360
2022 Q2	–	Sell	-270,737	Closed	-$2.47M	–	992
2022 Q1	$2.47M	Buy	+270,737	New	+$2.82M	0.02%	588

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jacobs Levy Equity Management's ALLO Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its Allogene Therapeutics (ALLO) stake by 28% in Q2 2026, selling an estimated $1.23M and leaving 1,455,103 shares worth $3.03M. The position accounts for 0.01% of the portfolio, ranked #515.

Jacobs Levy Equity Management first reported a position in ALLO in Q1 2022 and has held it in 6 quarters since. The position peaked at $5.78M in Q3 2022. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

Jacobs Levy Equity Management held 1,455,103 shares of Allogene Therapeutics worth $3.03M as of Q2 2026.
Jacobs Levy Equity Management sold 558,405 Allogene Therapeutics shares in Q2 2026, an estimated $1.23M.
Allogene Therapeutics made up 0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #515 holding.
Jacobs Levy Equity Management first reported a position in Allogene Therapeutics in Q1 2022 and has held it in 6 quarters since.
Jacobs Levy Equity Management's Allogene Therapeutics position peaked at $5.78M in Q3 2022.
210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.